Clinical Trials Logo
  1. Home
  2. Gallbladder Cancer
  3. NCT05559229
  4. Details
NCT05559229 Clinical Trial

Poorly Differentiated Adenocarcinoma With Signet Ring Cells of the Gallbladder Producing a High Level of Alpha-fetoprotein: a Case Report

Gallbladder Cancer Clinical Trial

Official title:
Poorly Differentiated Adenocarcinoma With Signet Ring Cells of the Gallbladder Producing a High Level of Alpha-fetoprotein: a Case Report

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05559229
Other study ID # oitaRCH
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 15, 2021
Est. completion date September 18, 2022

Study information
Verified date September 2022
Source Oita Red Cross Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Alpha-fetoprotein (AFP) can become elevated in hepatocellular carcinoma (HCC), yolk sac tumors and other malignant tumors of various organs. Herein, the investigator present a case of AFP-producing gallbladder carcinoma with signet ring cells successfully treated with laparoscopic whole-layer cholecystectomy.

Recruitment information / eligibility
Status Completed
Enrollment 1
Est. completion date September 18, 2022
Est. primary completion date June 25, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group N/A and older
Eligibility The study eligibility criteria for patient were as follows: AFP-producing gallbladder carcinoma (cT2aN0M0, cStage IIa, UICC 8th) or gallbladder metastasis from HCC.

Study Design

Related Conditions & MeSH terms

Intervention

Procedure:
• laparoscopic whole-layer cholecystectomy
laparoscopic whole-layer cholecystectomy.

Locations
Country Name City State
Japan oita Red Cross hospital Oita Oita

Sponsors (1)
Lead Sponsor Collaborator
junya mita

Country where clinical trial is conducted

Japan, 

Outcome
Type Measure Description Time frame Safety issue
Primary To evaluate the efficacy of measuring value of AFP for patients with gallbladder cancer. 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05237193 - A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Terminated NCT00903396 - Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Phase 2
Terminated NCT00896467 - Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy N/A
Withdrawn NCT00386516 - Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer Phase 2
Completed NCT00033540 - S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma Phase 2
Completed NCT00660699 - A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers Phase 2
Terminated NCT04066491 - Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC Phase 2/Phase 3
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Recruiting NCT05489250 - The PLATON Network
Recruiting NCT04484636 - PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study) N/A
Completed NCT00753675 - Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer Phase 2
Completed NCT00304135 - Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery Phase 2/Phase 3
Completed NCT00409864 - Endoscopic Versus Percutaneous Drainage For Hilar Block in Gall Bladder Cancer N/A
Completed NCT00084942 - Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder Phase 2
Recruiting NCT04445532 - Hepatobiliary Tumors Tissue Samples Acquisition
Terminated NCT00658593 - Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer Phase 3
Completed NCT00486356 - Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer Phase 1
Not yet recruiting NCT06134193 - Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer Phase 2